Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
NCT03884075 on ClinicalTrials.gov · last registry update 2026-08-10
Recruiting now, toward 104 participants. Due to report 3 September 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Histological Improvement. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 24 July 2019 — 7 years so far. semaglutide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- RECRUITING
- Phase
- P2
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Sponsor type
- Nih
- Enrollment
- 104
- Started
- 2019-07-24
- Primary completion
- 2027-09-03 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Histological Improvement
Conditions studied
Non-Alcoholic Steatohepatitis · Non-Alcoholic Fatty Liver Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.